Mike Waring

Mike Waring holds the chair of Medicinal Chemistry in the School of Chemistry at Newcastle University and is the chemistry lead for the discovery program at the Northern Institute for Cancer Research. Prior to this appointment, he was principal scientist in Medicinal Chemistry at AstraZeneca, UK. He is a highly experienced medicinal chemist with a track record of delivery of drug-discovery projects in oncology and cardiovascular indications, including 12 candidate drugs, six of which have thus far progressed to human trials and one has been approved by FDA (osimertinib, Tagrisso™). He has a keen interest in small-molecule drug discovery and the discovery of chemical probes as well as the development of novel hit generation and optimisation approaches.